Mastering EUDAMED in a scalable way: From a regulatory obligation to a compliance asset

EUDAMED has been mandatory for the first four modules since 28 May 2026. Many medtech manufacturers have now recognised registration as an operational challenge: data is scattered, reporting obligations are recurring, and teams in Regulatory Affairs and Quality Management are reaching their limits. However, the real decision has not yet been made. It is not a question of whether to comply with EUDAMED, but how: either laboriously by hand or as a scalable process that grows with the business. This article explains why it is worth setting this course now.

Four modules have been mandatory since May 2026: the registration of economic operators, product and UDI registration, certificates, and market surveillance. Two further modules – vigilance and clinical trials – will follow. For manufacturers, this means that the workload is spread across several modules, recurs regularly and increases with every new product. Existing products must be brought into compliance by 28 November 2026.

EUDAMED in practice: Why manual processes are reaching their limits

The reality in many companies is similar. Product data is scattered across Excel spreadsheets, ERP modules and legacy systems. For EUDAMED registration, this data has to be manually collated, prepared and entered into the portal. This works as long as the portfolio is small and stable.

With every new product and every additional module, this approach becomes unsustainable. The initial upload of a medium-sized portfolio can take weeks to complete manually. A single incorrectly assigned attribute leads to rejection. And the reporting obligations never end: master data changes, certificates expire, and incidents must be reported within the specified timeframes. Manual processing generates hidden costs, ties up qualified specialists and becomes a risk as the product range grows. This is precisely where isolated, ad-hoc solutions reach their limits.

From obligation to asset: a shift in regulatory strategy

The crucial step is a change of perspective. EUDAMED compliance is not a one-off effort before the deadline, but an ongoing process that grows alongside the portfolio. Those who treat it as such can also build it that way: as a clean, reusable architecture rather than a stand-alone solution for the next deadline.

The difference is strategic. A stand-alone solution addresses a single module for today. A scalable EUDAMED architecture supports all modules, grows with new products and integrates future requirements without the need to rebuild. A tedious obligation thus becomes a compliance asset: set up once, usable for the long term. Manufacturers of all sizes benefit from this, from small businesses with just a few products to large corporations with thousands of items.

Automation and integration: technical levers for scalable compliance

The key lies in integration. Instead of manually transferring data to the portal, a machine-to-machine (M2M) interface connects the existing IT systems directly to EUDAMED. Product data is then sourced from the ERP, MDM or PLM system, automatically validated prior to transfer and reported in a reproducible manner. This enables a structural reduction in manual effort.

The benefits are evident in every module. With the UDI module, uploading a large portfolio takes hours rather than weeks. For master data, there is no longer a need for constant reconciliation between the portal and the internal system.

For certificates, the quality management system automatically notifies staff when an approval is due to expire. And for vigilance reporting obligations, a reminder mechanism ensures compliance with statutory deadlines, even if a transfer fails for technical reasons. Notified Bodies also benefit: manually uploading batches of certificates for hundreds of customers is virtually impossible.

Crucially, this solution brings together multiple roles. Regulatory Affairs and Quality Management gain reliability and free up time for the actual assessment. IT and SAP managers become internal champions because the integration fits seamlessly into the existing system landscape, rather than creating yet another data silo. In this way, a regulatory obligation is transformed into a tangible example of Regulatory Affairs digitalisation.

A long-term partnership rather than a one-off project

A scalable solution requires a partner who will support the process beyond the deadline. This is because requirements continue to evolve. Further modules go live, the portfolio grows, and those supplying internationally encounter new databases. Switzerland, for example, is establishing its own database with Swissdamed: Registration there has been mandatory since 1 July 2026, and an M2M connection has also been possible since the end of March 2026. The same architecture can be used for both markets.

adesso supports medtech manufacturers and Notified Bodies precisely along this path: from assessing the current situation and selecting the appropriate methods to implementing the interfaces – in a tool-agnostic manner and integrated into the existing IT infrastructure. This ensures the solution remains viable even when new modules go live or the portfolio expands. Compliance-assured market access, automation and a reliable, scalable process are thus not a contradiction, but the very aim of a modern regulatory strategy.